Danaher (NYSE:DHR) had its price target hoisted by stock analysts at Citigroup to $107.00 in a research note issued on Friday. The firm presently has a “buy” rating on the conglomerate’s stock. Citigroup’s price target would indicate a potential upside of 15.24% from the stock’s previous close.
Other research analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a research report on Thursday, October 5th. Cowen reissued a “buy” rating and issued a $90.00 price target on shares of Danaher in a research report on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and issued a $83.00 price target on shares of Danaher in a research report on Tuesday, September 26th. Robert W. Baird increased their price target on shares of Danaher from $87.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. Finally, Credit Suisse Group increased their price target on shares of Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $94.05.
Danaher (NYSE DHR) opened at $92.85 on Friday. Danaher has a 52-week low of $77.66 and a 52-week high of $94.82. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00. The stock has a market cap of $65,491.23, a PE ratio of 24.20, a P/E/G ratio of 2.24 and a beta of 1.02.
In other news, Director Donald J. Ehrlich sold 10,578 shares of the firm’s stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the sale, the director now owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total transaction of $11,671,620.96. Following the sale, the chief executive officer now directly owns 271,737 shares of the company’s stock, valued at approximately $25,173,715.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 273,810 shares of company stock valued at $25,218,813. Company insiders own 12.20% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Danaher by 1.3% during the second quarter. Vanguard Group Inc. now owns 41,488,407 shares of the conglomerate’s stock valued at $3,501,206,000 after purchasing an additional 520,776 shares during the last quarter. BlackRock Inc. grew its stake in shares of Danaher by 3.2% during the second quarter. BlackRock Inc. now owns 39,201,798 shares of the conglomerate’s stock valued at $3,308,239,000 after purchasing an additional 1,233,876 shares during the last quarter. FMR LLC grew its stake in shares of Danaher by 0.9% during the second quarter. FMR LLC now owns 19,624,350 shares of the conglomerate’s stock valued at $1,656,100,000 after purchasing an additional 183,183 shares during the last quarter. Parnassus Investments CA grew its stake in shares of Danaher by 0.3% during the third quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock valued at $840,351,000 after purchasing an additional 29,381 shares during the last quarter. Finally, Flossbach Von Storch AG grew its stake in shares of Danaher by 17.2% during the third quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock valued at $581,324,000 after purchasing an additional 994,902 shares during the last quarter. 76.32% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This article was originally published by American Banking and Market News and is owned by of American Banking and Market News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/15/citigroup-boosts-danaher-dhr-price-target-to-107-00.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
